NDAINJECTIONINJECTABLE
Approved
Sep 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PHOSPHOCOL P32 (Chromic Phosphate P-32) is a radioactive diagnostic and therapeutic injectable approved in 1974. It is used for localization and treatment of certain malignancies and inflammatory conditions via intra-articular, intraperitoneal, or intrapleural administration. The agent works through selective uptake by reticuloendothelial cells and tumor tissue, delivering localized beta radiation.
LOE Approaching
As LOE approaches, the brand team is likely focused on lifecycle management and transition planning rather than growth initiatives, signaling smaller commercial teams and reduced hiring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PHOSPHOCOL P32 offers limited career advancement due to product maturity and approaching LOE. Roles focus on portfolio stewardship, compliance, and managed decline rather than innovation or market expansion.
Regulatory Affairs SpecialistProduct Manager (Legacy Portfolio)
Worked on PHOSPHOCOL P32 at Curium Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.